Chart-Typ:
Zeitraum:
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen |
| INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen |
| Polestar Reports Revenue Growth of 56% in the First Half of 2025 |
Strong retail sales volumes growth at 51% ahead of EV market with retail network expansion progressing at pace
Profitability reflects external headwinds
Raised USD 200 million of... ► Artikel lesen |
| Neue Zoll-Unsicherheiten belasten - Kraft Heinz, Affirm, Microsoft, Amazon, Ferrari, Polestar | Die US-Börsen starten erst heute in die neue Handelswoche. Gestern war die Wall Street aufgrund des "Labor Day"-Feiertages geschlossen. Bei den Einzelthemen geht es heute um Kraft Heinz, Affirm Holdings... ► Artikel lesen |
| Polestar Sets the Date for H1 2025 Results | Polestar (Nasdaq: PSNY) expects to publish H1 2025 unaudited financial results on 3 September 2025, before market open. Management will host a conference call at 14:00 Central European Time (08:00... ► Artikel lesen |
| Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update | Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to... ► Artikel lesen |
| Adaptimmune Therapeutics PLC: Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds | Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with GalapagosPurchase... ► Artikel lesen |
| Adaptimmune Therapeutics PLC: Adaptimmune Reports Q1 Financial Results and Provides Business Update | TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERAYAK POWER SOLUTION GROUP INC finden Sie auf Wallstreet Online.